DX 103Alternative Names: DX103; Mydriatic MicroRx
Latest Information Update: 20 Mar 2017
At a glance
- Originator Eyenovia
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase Unknown Mydriasis
Most Recent Events
- 08 Dec 2016 Investigation in Mydriasis in USA (Ophthalmic)
- 08 Dec 2016 Eyenovia plans a phase II/III trial for Mydriasis (Eyenovia pipeline, December 2016)